Levine Todd
Phoenix Neurological Associates, Phoenix, AZ, USA.
Drug Des Devel Ther. 2012;6:133-9. doi: 10.2147/DDDT.S33110. Epub 2012 Jun 11.
Effective and tolerable treatment options for patients with dermatomyositis and polymyositis are limited. This retrospective case review describes treatment with adrenocorticotropic hormone (ACTH) gel in five patients who experienced a disease exacerbation and either failed or were unable to tolerate the side effects of previous therapy with steroids, intravenous immunoglobulins, and steroid-sparing drugs.
Patients received ACTH gel subcutaneous injections of 80 U (1 mL) twice weekly (four patients) or once weekly (one patient) over the course of 12 weeks for short-term treatment of symptom exacerbations. Manual muscle testing using the Medical Research Council scale was assessed at baseline and at 3 months.
Improvement was seen in all patients, including improved muscle strength, decreased pain, and resolution of skin involvement. All patients tolerated the treatment well, and no significant side effects occurred.
The treatment of dermatomyositis and polymyositis is an approved use for ACTH gel, and these anecdotal reports would suggest consideration of ACTH gel as a therapeutic option. Further investigation is warranted.
皮肌炎和多发性肌炎患者有效的且可耐受的治疗选择有限。本回顾性病例分析描述了促肾上腺皮质激素(ACTH)凝胶对5例病情加重且对先前使用类固醇、静脉注射免疫球蛋白及类固醇替代药物治疗无效或无法耐受其副作用的患者的治疗情况。
患者接受ACTH凝胶皮下注射,剂量为80 U(1 mL),每周2次(4例患者)或每周1次(1例患者),疗程为12周,用于短期治疗症状加重情况。在基线和3个月时使用医学研究委员会量表进行手动肌力测试评估。
所有患者均有改善,包括肌肉力量增强、疼痛减轻和皮肤受累情况消退。所有患者对治疗耐受性良好,未出现明显副作用。
ACTH凝胶治疗皮肌炎和多发性肌炎是获批的用途,这些病例报告提示可考虑将ACTH凝胶作为一种治疗选择。有必要进行进一步研究。